Analytical Data
-
Gene name
Sp1
- Application
-
Alternative Names
TSFP1; Sp1 Transcription Factor
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P08047
-
Expression Region
Leu260~Ala591
-
Molecular Weight
63kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Sp1, a transcription factor belonging to the specificity protein/Krüppel-like factor (Sp/KLF) family, plays a pivotal role in regulating gene expression across various biological processes, including cell growth, differentiation, and apoptosis. The study of Sp1 recombinant proteins has gained significant interest due to its involvement in numerous diseases, including cancer, where aberrant expression can lead to tumor progression and metastasis. Researchers have focused on engineering Sp1 recombinant proteins to understand its structural properties and functional mechanisms more comprehensively. This involves creating both full-length and truncated forms of Sp1 to determine critical domains responsible for DNA binding and transcriptional activation. Recent advances in recombinant DNA technology, such as CRISPR and advanced protein expression systems, have facilitated the production and purification of Sp1 proteins, allowing for detailed biochemical characterization and interaction studies. Furthermore, the use of Sp1 as a potential therapeutic target or biomarker is under investigation, particularly in the context of targeted cancer therapies. Understanding Sp1’s role through its recombinant forms could provide insights into novel therapeutic strategies, contributing to the development of drugs that can modulate its activity, thereby offering hope for improving treatment outcomes in various diseases. Overall, the exploration of Sp1 recombinant proteins not only enhances our fundamental understanding of gene regulation but also paves the way for innovative clinical applications.
